Skip to main content

Peer Review reports

From: Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

Original Submission
11 May 2022 Submitted Original manuscript
20 May 2022 Reviewed Reviewer Report
23 Sep 2022 Reviewed Reviewer Report
9 Nov 2022 Author responded Author comments - Michio Imamura
11 Nov 2022 Author responded Author comments - Michio Imamura
Resubmission - Version 2
9 Nov 2022 Submitted Manuscript version 2
11 Nov 2022 Author responded Author comments - Michio Imamura
Resubmission - Version 3
11 Nov 2022 Submitted Manuscript version 3
12 Nov 2022 Reviewed Reviewer Report
12 Nov 2022 Reviewed Reviewer Report
15 Nov 2022 Author responded Author comments - Michio Imamura
Resubmission - Version 4
15 Nov 2022 Submitted Manuscript version 4
Publishing
16 Nov 2022 Editorially accepted
29 Nov 2022 Article published 10.1186/s12885-022-10327-7

You can find further information about peer review here.

Back to article page